Denali Therapeutics Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Denali Therapeutics Inc. (DNLI) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $5.47 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-02-26
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $5.47M.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6.28M.
- 2025-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $7.13M.
- 2025-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $8.02M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $5.47M 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.28M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $7.13M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $8.02M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $8.96M 10-K · filed 2025-02-27 |
| 2024-09-30 | $9.94M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $10.96M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $12.02M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $13.12M 10-K · filed 2024-02-28 |
| 2023-09-30 | $14.25M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $15.42M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $16.62M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $17.95M 10-K · filed 2023-02-27 |
| 2022-09-30 | $19.25M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $20.42M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $21.75M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $23.11M 10-K · filed 2022-02-28 |
| 2021-09-30 | $24.49M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $25.90M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $27.40M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $28.86M 10-K · filed 2021-02-26 |
| 2020-09-30 | $30.35M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $31.86M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $33.38M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $34.93M 10-K · filed 2020-02-27 |
| 2019-09-30 | $36.50M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $38.22M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $38.98M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |